This page is intended for UK healthcare professionals only.
FABHALTA® is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.1
FABHALTA®▼ (iptacopan) Connected – Stronger Together
Helping your eligible patients prescribed FABHALTA® start and stay on track with their treatment
Connected – Stronger Together is a patient support programme developed and funded by Novartis Pharmaceuticals UK Ltd.
It provides support to patients prescribed iptacopan to help them better understand and manage their paroxysmal nocturnal haemoglobinuria (PNH) and treatment.
Connected – Stronger Together, designed with the help of patients, provides information, resources, and support that specifically address the unique needs of your patients as they start their treatment with iptacopan and throughout their treatment journey.
The Connected – Stronger Together patient support programme can help patients:
Receive personalised support based on their specific challenges
Understand and manage possible side effects associated with their treatment
Learn more about their treatment
Access information about treatment tracking and monitoring
Learn more about PNH
Find information and sources of emotional and well-being support
Two simple ways for your patients to enrol
Patients prescribed iptacopan can help stay informed and adherent with their treatment by enrolling in Connected – Stronger Together
Online: www.fabhalta-cst.co.uk
Phone call: 01794 331 148
Support programme offerings and communication channels
Starter kit
A treatment starter pack that provides patients and their caregivers with information on PNH and treatment with iptacopan, along with a treatment guide, therapy diary, goal setting planner, appointment planner, contact card, and stickers for reminding patients to take their medication.
Nurse support
Inbound and outbound nurse calls for informational, logistical, and emotional support.
One-on-one personalised support from trained nurses can help patients be more comfortable and adherent with their treatment and disease management.2–4
Educational resources
Digital and print resources about PNH and iptacopan for tracking medication, symptoms, and mood over time, and for connecting with support networks. Online resources are available to patients at https://www.fabhalta-connected-stronger-together.co.uk.
Emails
Important topics related to PNH and treatment with iptacopan, including its mechanism of action, dosing, tips for establishing a medication routine, and side-effect management, plus links to additional information and resources on a website.
Emails with educational information can support patients with their treatment and provide links to download additional resources that can help with medication adherence.5
SMS text messages
Daily medication reminders help patients remain adherent with their medicines each day
Motivational texts help patients stay engaged while managing their disease and treatment
In studies, medical compliance reminders were found to improve medication regimen adherence when using an SMS-reminder intervention.5
HCP brochure
HCP, healthcare professional; PNH, paroxysmal nocturnal haemoglobinuria.
References
FABHALTA® Summary of Product Characteristics
Lee A, et al. J Med Internet Res 2022;24(11):e40364.
Ganguli A, et al. Patient Prefer Adherence 2016;10:711–725.
Kes D & Polat U. Int J Nurs Pract 2022 Jun;28(3):e12995.
Schwebel FJ & Larimer, ME. Internet Inventions 2018;13:82–104.
UK | March 2025 | FA-11270182-1
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
